Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 1
Submit an article Journal homepage
380
Views
70
CrossRef citations to date
0
Altmetric
Review

The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches

Iana H Haralambieva Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA
,
Inna G Ovsyannikova Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA
,
V Shane Pankratz Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA
,
Richard B Kennedy Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA
,
Robert M Jacobson Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
&
Gregory A Poland Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. [email protected]
Pages 57-70 | Published online: 09 Jan 2014

References

  • Simons E, Ferrari M, Fricks J et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379(9832), 2173–2178 (2012).
  • MMWR. Measles – United States, January–May 20, 2011. MMWR Morb. Mortal Wkly Rep. 20, 666–668 (2011).
  • MMWR. Measles – United States, 2011. MMWR Morb. Mortal Wkly Rep. 61, 253–257 (2012)
  • Chen SY, Anderson S, Kutty PK et al. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. J. Infect. Dis. 203(11), 1517–1525 (2011).
  • Sanders R, Dabbagh A, Featherstone D. Risk analysis for measles reintroduction after global certification of eradication. J. Infect. Dis. 204(Suppl. 1), S71–S77 (2011).
  • Moss WJ. Measles control and the prospect of eradication. Curr. Top. Microbiol. Immunol. 330, 173–189 (2009).
  • Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 114(4), 1065–1069 (2004).
  • Elliman D, Sengupta N. Measles. Curr. Opin. Infect. Dis. 18(3), 229–234 (2005).
  • Poland GA, Jacobson RM. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch. Intern. Med. 154(16), 1815–1820 (1994).
  • Parker Fiebelkorn A, Redd SB, Gallagher K et al. Measles in the United States during the postelimination era. J. Infect. Dis. 202(10), 1520–1528 (2010).
  • Poland GA, Jacobson RM, Thampy AM et al. Measles reimmunization in children seronegative after initial immunization. JAMA 277(14), 1156–1158 (1997).
  • Seward JF, Orenstein WA. A rare event: a measles outbreak in a population with high 2-dose measles vaccine coverage. Clin. Infect. Dis. 55(3), 403–405 (2012).
  • De Serres G, Boulianne N, Defay F et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin. Infect. Dis. 55(3), 394–402 (2012).
  • Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am. J. Epidemiol. 148(11), 1103–1110 (1998).
  • Mathias RG, Meekison WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. Am. J. Public Health 79(4), 475–478 (1989).
  • Sugerman DE, Barskey AE, Delea MG et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 125(4), 747–755 (2010).
  • Haralambieva IH, Ovsyannikova IG, O’Byrne M, Pankratz VS, Jacobson RM, Poland GA. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 29(27), 4485–4491 (2011).
  • Pannuti CS, Morello RJ, Moraes JC et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin. Diagn. Lab. Immunol. 11(1), 119–122 (2004).
  • Hickman CJ, Hyde TB, Sowers SB et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J. Infect. Dis. 204(Suppl. 1), S549–S558 (2011).
  • Glass K, Grenfell BT. Waning immunity and subclinical measles infections in England. Vaccine 22(29–30), 4110–4116 (2004).
  • Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am. J. Epidemiol. 150(11), 1238–1249 (1999).
  • Umlauf BJ, Haralambieva IH, Ovsyannikova IG et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol. 25(1), 29–36 (2012).
  • Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine 30(2), 103–104 (2012).
  • Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 25(21), 4170–4174 (2007).
  • Wong-Chew RM, García-León ML, Espinosa-Torres Torrija B et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J. Infect. Dis. 204(3), 426–432 (2011).
  • Simon JK, Ramirez K, Cuberos L et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin. Vaccine Immunol. 18(3), 355–361 (2011).
  • Taking the initiative. Lancet Infect. Dis. 5(12), 733 (2005).
  • Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J. Infect. Dis. 204(Suppl. 1), S133–S148 (2011).
  • Griffin DE, Moss WJ. Can we eradicate measles? Microbe 1(9), 409–413 (2006).
  • Davey S. Measles eradication still a long way off. Bull. WHO (2001).
  • Moss WJ, Strebel P. Biological feasibility of measles eradication. J. Infect. Dis. 204(Suppl. 1), S47–S53 (2011).
  • de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL. Measles vaccination: new strategies and formulations. Expert Rev. Vaccines 7(8), 1215–1223 (2008).
  • Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 15(9), 625–636 (2011).
  • Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog. 7(12), e1002344 (2011).
  • Oberg AL, Kennedy RB, Li P, Ovsyannikova IG, Poland GA. Systems biology approaches to new vaccine development. Curr. Opin. Immunol. 23(3), 436–443 (2011).
  • Haralambieva IH, Poland GA. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol. 5(12), 1757–1760 (2010).
  • Poland GA, Oberg AL. Vaccinomics and bioinformatics: accelerants for the next golden age of vaccinology. Vaccine 28(20), 3509–3510 (2010).
  • Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 10(5), 837–852 (2009).
  • Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82(6), 653–664 (2007).
  • Seib KL, Dougan G, Rappuoli R. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet. 5(10), e1000612 (2009).
  • Sirskyj D, Diaz-Mitoma F, Golshani A, Kumar A, Azizi A. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol. Cell Biol. 89(1), 81–89 (2011).
  • Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J. Clin. Invest. 119(9), 2515–2525 (2009).
  • Kennedy RB, Poland GA. The top five “game changers” in vaccinology: toward rational and directed vaccine development. OMICS 15(9), 533–537 (2011).
  • Bernstein A, Pulendran B, Rappuoli R. Systems vaccinomics: the road ahead for vaccinology. OMICS 15(9), 529–531 (2011).
  • Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines. Immunol. Rev. 239(1), 197–208 (2011).
  • Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741–747 (2009).
  • Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116–125 (2009).
  • Stittelaar KJ, Hoogerhout P, Ovaa W et al. In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine 20(1–2), 249–261 (2002).
  • Poland GA, Ovsyannikova IG, Jacobson RM et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20(3–4), 430–438 (2001).
  • Jacobson RM, Poland GA, Vierkant RA et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum. Immunol. 64(1), 103–109 (2003).
  • Ovsyannikova IG, Ryan JE, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Immunologic significance of HLA class I genes in measles virus-specific IFN-g and IL-4 cytokine immune responses. Immunogenetics 57(11), 828–836 (2005).
  • Ovsyannikova IG, Jacobson RM, Ryan JE et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56(11), 798–807 (2005).
  • Ovsyannikova IG, Ryan JE, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and interleukin 2, 10 and 12p40 cytokine responses to measles: is there evidence of the HLA effect? Cytokine 36(3–4), 173–179 (2006).
  • Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J. Infect. Dis. 193(5), 655–663 (2006).
  • Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 25(16), 3090–3100 (2007).
  • Jacobson RM, Ovsyannikova IG, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose. Vaccine 29(45), 7982–7991 (2011).
  • Ovsyannikova IG, Jacobson RM, Vierkant RA, Shane Pankratz V, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22(15–16), 1914–1920 (2004).
  • St Sauver JL, Ovsyannikova IG, Jacobson RM et al. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185(11), 1545–1549 (2002).
  • Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6(2), 95–108 (2005).
  • Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat. Genet. 29(3), 306–309 (2001).
  • Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 30(12), 2146–2152 (2012).
  • Kennedy RB, Ovsyannikova IG, Haralambieva IH et al. Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine 30(12), 2159–2167 (2012).
  • White SJ, Haralambieva IH, Ovsyannikova IG, Vierkant RA, O’Byrne MM, Poland GA. Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes. Hum. Immunol. 73(6), 636–640 (2012).
  • Dhiman N, Ovsyannikova IG, Cunningham JM et al. Associations between measles vaccine immunity and single nucleotide polymorphisms in cytokine and cytokine receptor genes. J. Infect. Dis. 195, 21–29 (2007).
  • Dhiman N, Poland GA, Cunningham JM et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J. Allergy Clin. Immunol. 120(3), 666–672 (2007).
  • Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine. Pharmacogenet. Genomics 22(1), 20–31 (2012).
  • Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms. Hum. Hered. 72(3), 206–223 (2011).
  • Haralambieva IH, Ovsyannikova IG, Umlauf BJ et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 29(48), 8988–8997 (2011).
  • Haralambieva IH, Ovsyannikova IG, Kennedy RB et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 29(45), 7883–7895 (2011).
  • Yoo KH, Agarwal K, Butterfield M, Jacobson RM, Poland GA, Juhn YJ. Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma. Allergy Asthma Proc. 31(6), 499–506 (2010).
  • Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens 72(3), 211–220 (2008).
  • Dhiman N, Ovsyannikova IG, Vierkant RA et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26(14), 1731–1736 (2008).
  • Poland GA, Ovsyannikova IG, Jacobson RM. Genetics and immune response to vaccines. In: Genetic Susceptibility to Infectious Diseases. Kaslow RA, McNicholl JM, Hill AVS (Eds). Oxford University Press, Oxford, UK, 1–447 (2008).
  • Clifford HD, Yerkovich ST, Khoo SK et al. TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum. Immunol. 73(6), 677–685 (2012).
  • Clifford HD, Hayden CM, Khoo SK, Zhang G, Le Souëf PN, Richmond P. CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. Clin. Vaccine Immunol. 19(5), 704–710 (2012).
  • Clifford HD, Yerkovich ST, Khoo SK et al. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics 64(3), 219–228 (2012).
  • Clifford HD, Richmond P, Khoo SK et al. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine 29(33), 5407–5413 (2011).
  • Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. Twin studies of immunogenicity – determining the genetic contribution to vaccine failure. Vaccine 19(17–19), 2434–2439 (2001).
  • Pankratz VS, Vierkant RA, O’Byrne MM, Ovsyannikova IG, Poland GA. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol. 11, 48 (2010).
  • Fridley BL, Lund S, Jenkins GD, Wang L. A Bayesian integrative genomic model for pathway analysis of complex traits. Genet. Epidemiol. 36(4), 352–359 (2012).
  • Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75(2), 295–305 (1993).
  • Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406(6798), 893–897 (2000).
  • Mühlebach MD, Mateo M, Sinn PL et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480(7378), 530–533 (2011).
  • Noyce RS, Bondre DG, Ha MN et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 7(8), e1002240 (2011).
  • Noyce RS, Richardson CD. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol. 20(9), 429–439 (2012).
  • Zwiers A, Seegers D, Heijmans R et al. Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn’s disease. Genes Immun. 5(8), 675–677 (2004).
  • Seegers D, Zwiers A, Strober W, Peña AS, Bouma G. A TaqI polymorphism in the 3’UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun. 3(7), 419–423 (2002).
  • Houldsworth A, Metzner M, Rossol S et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J. Interferon Cytokine Res. 25(5), 271–276 (2005).
  • Morahan G, Kaur G, Singh M et al. Association of variants in the IL12B gene with leprosy and tuberculosis. Tissue Antigens 69(Suppl. 1), 234–236 (2007).
  • Morahan G, McKinnon E, Berry J et al.; Type I Diabetes Genetics Consortium. Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun. 10(Suppl. 1), S64–S68 (2009).
  • Yucesoy B, Johnson VJ, Fluharty K et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 27(50), 6991–6997 (2009).
  • Chorley BN, Wang X, Campbell MR, Pittman GS, Noureddine MA, Bell DA. Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current and developing technologies. Mutat. Res. 659(1–2), 147–157 (2008).
  • Buckland PR. The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim. Biophys. Acta 1762(1), 17–28 (2006).
  • Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. 32(1), 79–90 (2010).
  • Hoffmann SC, Stanley EM, Darrin Cox E et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72(8), 1444–1450 (2001).
  • Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39(4), 978–988 (2004).
  • Cox AJ, Gleeson M, Pyne DB, Callister R, Fricker PA, Scott RJ. Cytokine gene polymorphisms and risk for upper respiratory symptoms in highly-trained athletes. Exerc. Immunol. Rev. 16, 8–21 (2010).
  • Yilmaz V, Demirbilek V, Gürses C et al. Interleukin (IL)-12, IL-2, interferon-g gene polymorphisms in subacute sclerosing panencephalitis patients. J. Neurovirol. 13(5), 410–415 (2007).
  • International HapMap Consortium. A haplotype map of the human genome. Nature 437(7063), 1299–1320 (2005).
  • Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 322(5903), 881–888 (2008).
  • Gibson G. Hints of hidden heritability in GWAS. Nat. Genet. 42(7), 558–560 (2010).
  • Altshuler DM, Gibbs RA, Peltonen L et al.; International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52–58 (2010).
  • A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061–1073 (2010).
  • Kondilis-Mangum HD, Wade PA. Epigenetics and the adaptive immune response. Mol. Aspects Med. (2012).
  • Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9(2), 91–105 (2009).
  • Holden M, Deng S, Wojnowski L, Kulle B. GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics 24(23), 2784–2785 (2008).
  • Patterson N, Hattangadi N, Lane B et al. Methods for high-density admixture mapping of disease genes. Am. J. Hum. Genet. 74(5), 979–1000 (2004).
  • McCarroll SA, Kuruvilla FG, Korn JM et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat. Genet. 40(10), 1166–1174 (2008).
  • Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 37(Web Server issue), W600–W605 (2009).
  • Liu CK, Chen YH, Tang CY et al. Functional analysis of novel SNPs and mutations in human and mouse genomes. BMC Bioinformatics 9(Suppl. 12), S10 (2008).
  • Fridley BL, Iversen E, Tsai YY, Jenkins GD, Goode EL, Sellers TA. A latent model for prioritization of SNPs for functional studies. PLoS ONE 6(6), e20764 (2011).
  • Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. Nat. Rev. Genet. 10(5), 318–329 (2009).
  • Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661–678 (2007).
  • Katayama Y, Hirano A, Wong TC. Human receptor for measles virus (CD46) enhances nitric oxide production and restricts virus replication in mouse macrophages by modulating production of a/b interferon. J. Virol. 74(3), 1252–1257 (2000).
  • Schneider U, von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76(15), 7460–7467 (2002).
  • Le Bon A, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176(4), 2074–2078 (2006).
  • Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine and consumer culture and vaccinomics. Vaccine 27(25–26 Special Issue), 3240–3244 (2009).
  • Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr. Infect. Dis. J. 28(5), 431–432 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.